The Development of Live Attenuated Mumps Virus Vaccine in Historic Perspective and Its Role in the Evolution of Combined Measles–Mumps–Rubella

  • Maurice R. Hilleman
Chapter

Abstract

Diseases with distinctive clinical features can often be identified with occurrence in early history. Hippocrates has been credited with clinical descriptions of mumps, parotitis and orchitis in thea fifth century BC [1]. Hamilton [2] is credited with the first recognition, in 1790, of central nervous system involvement in mumps and with the first description of neuropathology in fatal cases. Johnson and Goodpasture [3, 4] provided the first definitive evidence of viral etiology in mumps through monkey and human experimentation. Cultivation of mumps virus in embryonated hens’ eggs was accomplished by Habel in 1945 [5].

References

  1. 1.
    Cochi SL, Wharton M. Plotkin SA. Mumps vaccine. In: Plotkin SA, Mortimer ES Jr, eds. Vaccines Philadelphia: WB Saunders, 1994:277–301Google Scholar
  2. 2.
    Hamilton R. An account of a distemper by the common people of England vulgarly called the mumps. London med J 1790; (1) 190–211Google Scholar
  3. 3.
    Johnson CD, Goodpasture EW. An investigation of the etiology of mumps. J Exp Med 1934;59:1–19PubMedCrossRefGoogle Scholar
  4. 4.
    Johnson CD, Goodpasture E. The etiology of mumps. Am J Hyg 1935;21:46–57Google Scholar
  5. 5.
    Habel K. Cultivation of mumps virus in the developing chick embryo and its application to studies of immunity to mumps in man. Public Health Rep 1945;60:201–12Google Scholar
  6. 6.
    Rima BK. Mumps Virus. In: Webster RG, Granoff A, eds. Encyclopedia of Virology. London: Academic Press, 1994;2:876–83Google Scholar
  7. 7.
    Wolinsky JS, Waxham MN. Mumps virus. In: Fields BN, Knipe DM, eds. Virology. New York: Raven Press, 1990;2nd ed:989–1011Google Scholar
  8. 8.
    Nussinovitch M, Volvovitz B, Varsana I. Complications of mumps requiring hospitalization in children. Eur J Pediatr 1995;154:732–4PubMedCrossRefGoogle Scholar
  9. 9.
    Hilleman MR, Buynak EB, Weibel RE, Stokes J Jr. Live, attenuated mumps-virus vaccine. N Engl Med 1968;278:227–32CrossRefGoogle Scholar
  10. 10.
    Hilleman MR. Past, present, and future of measles, mumps and rubella virus vaccines. Pediatrics 1992;90:149–53PubMedGoogle Scholar
  11. 11.
    Weibel RE, Buynak EB, McLean AA, Hilleman MR. Follow-up surveillance for antibody in human subjects following live attenuated measles, mumps and rubella virus vaccines. Proc Soc Exp Biol Med 1979;162:328–32PubMedGoogle Scholar
  12. 12.
    Weibel RE, Buynak EB, McLean AA, Roehm RR, Hilleman MR. Persistance of antibody in human subjects for seven to ten years following administration of combined live attenuated measles, mumps and rubella virus vaccines. Proc Soc Exp Biol Med 1980;165:260–3PubMedGoogle Scholar
  13. 13.
    Smorodintsev AA, Klyachko NS. Mumps live vaccine in the USSR: a summary of recent developments. Prog Med Virol 1961;3:273–86Google Scholar
  14. 14.
    Cizman M, Mozetic M, Furman-Jakopic M, Pleterski-Rigler D, Radescek-Rakar R, Susec-Michieli M. Aseptic meningitis following combined vaccination with the Leningrad-3 strain of mumps virus and the Edmonston-Zagreb strain of measles virus. Zdrav Vestn 1986;55:587–91Google Scholar
  15. 15.
    Penttinen K, Cantell K, Somer P, Poikolianen A. Mumps vaccination in the Finnish defense forces. Am J Epidemiol 1968;39:363–71Google Scholar
  16. 16.
    Buynak EB, Hilleman MR. Live attenuated mumps virus vaccine. I. Vaccine development. Proc Soc Exp Biol Med 1966;123:768–75PubMedGoogle Scholar
  17. 17.
    Stokes H Jr., Weibel RE, Buynak EB, Hilleman MR. Live attenuated mumps-virus vaccine. II. Early clinical studies. Pediatrics 1967;39:363–71PubMedGoogle Scholar
  18. 18.
    Weibel RE, Stokes J Jr., Buynak EB, Whitman JE Jr., Hilleman MR. Live attenuated mumps-virus vaccine 3. Clinical and serological aspects in a field evaluation. N Engl J Med 1967;276:245–51Google Scholar
  19. 19.
    Hilleman MR, Weibel RE, Buynak EB, Stoke J Jr., Whitman JE Jr. Live attenuated mumps-virus vaccine. 4. Protective efficacy as measured in a field evaluation. N Engl J Med 1967;276:252–8Google Scholar
  20. 20.
    Buynak EB, Whitman JE Jr., Roehm RR, Morton DH, Lampson GP, Hilleman MR. Comparisons of neutralization and hemagglutination-inhibition techniques for measuring mumps antibody. Proc Soc Exp Biol Med 1967;125:1068–71PubMedGoogle Scholar
  21. 21.
    Davidson WL, Buynak EB, Leagus MB, Whitman JE Jr., Hilleman MR. Vaccination of adults with live attenutatied mumps virus vaccine. JAMA 1967;201:995–8PubMedCrossRefGoogle Scholar
  22. 22.
    Hilleman MR. Mumps vaccination. In: Heath RB, Waterson AP, eds. Modern Trends in Medical Virology. London: Butterworths, 1970;241–61Google Scholar
  23. 23.
    Buynak EB, Hilleman MR, Leagus MB, Whitman JE Jr., Weibel RE, Stokes J Jr. Jeryl Lynn strain live attenuated mumps virus vaccine: Influence of age, virus dose, lot, and γ-globulin administration on response. JAMA 1968;203:9–13Google Scholar
  24. 24.
    McAleer WJ, Markus HZ, McLean AA, Buynak EB, Hilleman MR. Stability on storage at various temperatures of live measles, mumps, and rubella virus vaccines in new stabilizer. J Biol Stand 1980;8:281–7PubMedCrossRefGoogle Scholar
  25. 25.
    Gut JP, Lablache C, Behr S, Kim A. Symptomatic mumps virus reinfections. J Med Virol 1995;45:17–23PubMedCrossRefGoogle Scholar
  26. 26.
    Hilleman MR, Stokes J Jr., Buynak EB, Weibel R, Halenda R, Goldner H. Enders’ live measles virus vaccine with human immune globulin. 2. Evaluation of efficacy. Am J Dis Child 1962;103:373–9Google Scholar
  27. 27.
    Hilleman MR, Buynak EB, Weibel RE, Stokes J Jr., Whitman JE Jr., Leagus MB. Development and evaluation of the Moraten measles virus vaccine. JAMA 1968;206:587–90PubMedCrossRefGoogle Scholar
  28. 28.
    Rubin H. A virus in chick embryos which induces resistance in vitro to infection with rous sarcoma virus. Proc Natl Acad Sci USA 1960;46:1105–19PubMedCrossRefGoogle Scholar
  29. 29.
    Hughes WF, Watanabe DH, Rubin H. The development of a chicken flock apparently free of leukosis virus. Avian Dis 1963;7:154–65CrossRefGoogle Scholar
  30. 30.
    World Health Organization: Meningitis associated with measles-mumps-rubella vaccines. Weekly Epidemiological Record 1992;67:301–2Google Scholar
  31. 31.
    Forsey T, Bentley ML, Minor PD, Begg N. Mumps vaccines and meningitis. Lancet 1992;340:980CrossRefGoogle Scholar
  32. 32.
    Miller E, Goldacri M, Pugh S et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993;341:979–82PubMedCrossRefGoogle Scholar
  33. 33.
    Schmitt HJ, Just M, Neiss A. Withdrawal of a mumps vaccine: reasons and impacts. Eur J Pediatr 1993;152:387–8PubMedCrossRefGoogle Scholar
  34. 34.
    Fures J. Vaccine-related mumps meningitis-Canada. Can Dis Weekly Rep 1990;16–50:253–4Google Scholar
  35. 35.
    Motegi Y, Fijinaga T, Tamura H, Kuroume T. A survey of children with meningitis following measles, mumps, and rubella (MMR) immunization. Pediatr Res 1990;27:95A (Abstr 558)Google Scholar
  36. 36.
    Yawata M. Japan’s troubles with measles-mumps-rubella vaccine. Lancet 1994;343:105–6CrossRefGoogle Scholar
  37. 37.
    Sawada H, Yano S, Oka Y, Togashi T. Transmission of Urabe mumps vaccine between siblings. Lancet 1993;342:371PubMedCrossRefGoogle Scholar
  38. 38.
    Afzal MA, Pickford AR, Forsey T, Heath AB, Minor PD. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates, J Gen Virol 1993;74:917–20PubMedCrossRefGoogle Scholar
  39. 39.
    Künkel U, Driesel G, Henning U, Gerike E, Willers H, Schreier E. Differentiation of vaccine and wild mumps viruses by polymerase chain reaction and nucleotide sequencing of the SH gene: brief report. J Med Virol 1995;45:121–6PubMedCrossRefGoogle Scholar
  40. 40.
    Hilleman MR, Weibel RE, Buynak EB, Villarejos VM. Practical aspects concerning combined live viral vaccines. Schweiz Rundschau Med (PRAXIS) 1975;64:98–108Google Scholar
  41. 41.
    Katz SL, Enders JF. Immunization of children with a live attenuated measles virus. Am J Dis Child 1959;98:605–7Google Scholar
  42. 42.
    Stokes J Jr., Weibel RE, Buynak EB, Hilleman MR. Clinical and laboratory tests of Merck strain live attenuated rubella virus vaccine. First International Conference on Vaccines against Viral and Rickettsial Diseases of Man, Washington, DC, 7–11 November 1966. Pan America Health Organization Sci Publ No 147. 1967;402–5Google Scholar
  43. 43.
    Buynak EB, Hilleman MR, Weibel RE, Stokes J Jr. Live attenuated rubella virus vaccines prepared in duck embryo cell culture. I. Development and clinical testing. JAMA 1968;204:195–200PubMedCrossRefGoogle Scholar
  44. 44.
    Weibel RE, Stokes J Jr., Buynak EB, Whitman JE Jr., Leagus MB, Hilleman MR. Live attenuated rubella virus vaccines prepared in duck embryo cell culture. II. Clinical tests in families and in an institution. JAMA 1968;205:554–8Google Scholar
  45. 45.
    Hilleman MR, Buynak EB, Weibel RE, Stokes J Jr. Current concepts. Live, attenuated rubella-virus vaccines. New Engl J Med 1968;279:300–3Google Scholar
  46. 46.
    Hilleman MR, Buynak EB, Whitman JE Jr., Weibel RE, Stokes J Jr. Summary report on rubella virus vaccines prepared in duck embryo cell culture. Symp Series Immunobiol Stand 1969;11:349–56Google Scholar
  47. 47.
    Weibel RE, Stokes J Jr., Buynak EB, Hillman MR. Live rubella vaccines in adults and children. HPV-77 and Merck-Benoit strains. Am J Dis Child 1969;118:226–9PubMedGoogle Scholar
  48. 48.
    Meyer HM JR., Parkman PD, Panis TC. Attenuated rubella virus. II. Production of experimental live-virus vaccine and clinical trial. N Engl J Med 1966;275:575–80Google Scholar
  49. 49.
    Hilleman MR, Buynak EB, Whitman JE Jr., Weibel RE, Stokes J Jr. Live attenuated rubella virus vaccines. Experiences with duck embryo cell preparations. Am J Dis Child 1969;118:166–71PubMedGoogle Scholar
  50. 50.
    Buynak EB, Larson VM, McAleer WJ, Mascoli CC, Hilleman MR. Preparation and testing of duck embryo cell culture rubella vaccine. Am J Dis Child 1969;118:347–54PubMedGoogle Scholar
  51. 51.
    Plotkin SA, Farquhar JD, Katz M, Buser F. Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am J Dis Child 1969;118:178–85PubMedGoogle Scholar
  52. 52.
    Weibel RE, Villarejos VM, Klein EB, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of live attenuated RA27/3 and HPV-77-DE rubella virus vaccines. Proc Soc Exp Biol Med 1980;165:44–9PubMedGoogle Scholar
  53. 53.
    Weibel RE, Carlson AJ Jr., Villarejos VM, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA27/3 rubella virus. Proc Soc Exp Biol Med 1980;165:323–6PubMedGoogle Scholar
  54. 54.
    Weibel RE, Stokes J Jr., Villarejos VM, Arguedas GJA, Buynak EB, Hilleman MR. Combined live rubella-mumps virus vaccine. Findings in clinical-laboratory studies. JAMA 1971;216:983–6PubMedCrossRefGoogle Scholar
  55. 55.
    Villarejos VM, Arguedas GJA, Buynak EB, Weibel RE, Stokes J Jr., Hilleman MR. Combined live measles-rubella virus vaccine. J Pediatr 1971;79:599–604PubMedCrossRefGoogle Scholar
  56. 56.
    Buynak EB, Weibel RE, Whitman JE Jr., Stoke J Jr., Hilleman MR. Combined live measles, mumps, and rubella virus vaccines. JAMA 1969;207:2259–62PubMedCrossRefGoogle Scholar
  57. 57.
    Hilleman MR, Weibel RE, Villarejos VM, et al. Combined live virus vaccines. Proceedings of the International Conference on the Application of Vaccines against Viral, Rickettsial, and Bacterial Diseases of Man, Washington DC, 14–18 December 1970. Pan American Health Organization Sci Publ No 226. 1971;397–400Google Scholar
  58. 58.
    Stokes J Jr., Weibel RE, Villarejos VM, Arguedas GJA, Buynak EB, Hilleman MR. Trivalent combined measles-mumps-rubella vaccine. Findings in clinical laboratory studies. JAMA 1971;218:57–61PubMedCrossRefGoogle Scholar
  59. 59.
    Weibel RE, Villarejos VM, Hernández CG, Stokes J Jr., Buynak EB, Hilleman MR. Combined live measles-mumps virus vaccine. Findings in clinical-laboratory studies. Arch Dis Child 1973;48:532–6Google Scholar
  60. 60.
    Plotkin SA, Rubin SA. Mumps vaccines. Vaccines 2008, 5th ed. pp: 435–466. W.B. Saunders, PhiladelphiaGoogle Scholar
  61. 61.
    Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: A historical perspective on unexpected elements. Vaccine 2009;27:6186–95PubMedCrossRefGoogle Scholar
  62. 62.
    Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps ­vaccines effective enough to prevent outbreaks? Clin Infect Dis 2008;47:1458–67PubMedCrossRefGoogle Scholar
  63. 63.
    Dominquez A, Tormer N, Castilla J, et al. Mumps vaccine effectiveness in highly immunized populations. Vaccine 2010;28:3567–70CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Maurice R. Hilleman
    • 1
  1. 1.West PointUSA

Personalised recommendations